ResMed (RMD) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating on the stock.
ResMed (RMD) was given a new $255.00 price target by Evercore Inc. They now have an "outperform" rating on the stock.
ResMed (RMD) had its price target lowered by Citigroup Inc. from $345.00 to $340.00. They now have a "buy" rating on the stock.
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
Is It Time To Revisit ResMed (RMD) After Recent Share Price Weakness? [Yahoo! Finance]